scholarly journals PHAGE-2 Study: Supplemental Bacteriophages Extend Bifidobacterium animalis subsp. lactis BL04 Benefits on Gut Health and Microbiota in Healthy Adults

Nutrients ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2474
Author(s):  
Diana S. Grubb ◽  
Scott D. Wrigley ◽  
Kimberley E. Freedman ◽  
Yuren Wei ◽  
Allegra R. Vazquez ◽  
...  
Keyword(s):  
Short Chain Fatty Acid ◽  
Controlled Trial ◽  
Microbial Populations ◽  
Gut Health ◽  
Double Blind ◽  
16S Rrna Analysis ◽  
Bifidobacterium Animalis ◽  
Gut Function ◽  
Self Assessments ◽  
Gi Inflammation

Probiotics are increasingly used by consumers and practitioners to reduce gastrointestinal (GI) distress and improve gut function. Here, we sought to determine whether the addition of supplemental bacteriophages (PreforPro) could enhance the effects of a common probiotic, Bifidobacterium animalis subsp. lactis (B. lactis) on GI health. A total of 68 participants were enrolled in a 4-week, randomized, parallel-arm, double-blind, placebo-controlled trial where primary outcomes included self-assessments of GI health, a daily stool log, and 16s rRNA analysis of gut microbial populations. We observed within-group improvements in GI inflammation (p = 0.01) and a trending improvement in colon pain (p = 0.08) in individuals consuming B. lactis with PreforPro, but not in the group consuming only the probiotic. There was also a larger increase in Lactobacillus and short-chain fatty acid-producing microbial taxa detected in the stool of participants taking PreforPro with B. lactis compared to the probiotic alone. Overall, these results suggest the addition of PreforPro as a combination therapy may alter gut ecology to extend the GI benefits of consuming B. lactis or other probiotics.

scholarly journals PHAGE-2 Study: Supplemental Bacteriophages Extend Bifidobacterium animals subsp. lactis BL04 Benefits on Gut Health and Microbiota

2020 ◽  
Author(s):  
Diana S. Grubb ◽  
Scott D Wrigley ◽  
Kimberley E Freedman ◽  
Yuren Wei ◽  
Allegra R Vazquez ◽  
...  
Keyword(s):  
Short Chain Fatty Acid ◽  
Controlled Trial ◽  
Microbial Populations ◽  
Gut Health ◽  
Double Blind ◽  
16S Rrna Analysis ◽  
Bifidobacterium Animalis ◽  
Gut Function ◽  
Self Assessments ◽  
Gi Inflammation

Probiotics are increasingly used by consumers and practitioners to reduce gastrointestinal (GI) distress and improve gut function. Here, we sought to determine whether addition of supplemental bacteriophages (PreforPro) could enhance the effects of a common probiotic, Bifidobacterium animalis subsp. lactis (B. lactis) on GI health. We conducted a 4-week, randomized, parallel-arm, double-blind, placebo-controlled trial where primary outcomes included self-assessments of GI health, a daily stool log, and 16s rRNA analysis of gut microbial populations. We observed within group improvements in GI inflammation (p=0.01) and a trending improvement in colon pain (p=0.08) in individuals consuming B. lactis with PreforPro, but not in the group consuming only the probiotic. There was also a larger increase in Lactobacillus and short chain fatty acid-producing microbial taxa detected in stool of participants taking PreforPro with B. lactis compared to the probiotic alone. Overall, these results suggest the addition of PreforPro as a combination therapy may alter gut ecology to extend the GI benefits of consuming B. lactis or other probiotics.

scholarly journals The Effects of Probiotic Supplementation on Anthropometric Growth and Gut Microbiota Composition in Patients With Prader-Willi Syndrome: A Randomized Double-Blinded Placebo-Controlled Trial

2021 ◽  
Vol 8 ◽  
Author(s):  
Xue-Jun Kong ◽  
Guobin Wan ◽  
Ruiyi Tian ◽  
Siyu Liu ◽  
Kevin Liu ◽  
...  
Keyword(s):  
Gut Microbiome ◽  
Therapeutic Potential ◽  
Controlled Trial ◽  
Genetic Disorder ◽  
Prader Willi Syndrome ◽  
Gut Health ◽  
Double Blind ◽  
Microbiome Composition ◽  
Bifidobacterium Animalis ◽  
Probiotic Treatment

Background: Prader-Willi Syndrome (PWS) is a rare genetic disorder associated with developmental delay, obesity, and neuropsychiatric comorbidities. Bifidobacterium animalis subsp. lactis has demonstrated anti-obesity and anti-inflammatory effects in previous studies.Aim: To evaluate the effects of Bifidobacterium animalis subsp. lactis probiotics supplementation on anthropometric growth, behavioral symptoms, and gut microbiome composition in patients with PWS.Methods: Ethical Approval was issued by the Internal Review Board (IRB) of the Second Affiliated Hospital of Kunming Medical University (Review-YJ-2016-06). We conducted a 12-week, randomized, double-blind, placebo-controlled trial in 68 patients with Prader-Willi syndrome aged 11 months−16 years (mean = 4.2 years old) who were randomly assigned to receive daily B. lactis-11 probiotics (6 × 1010 CFUs) or a placebo sachet. Weight, height, ASQ-3, ABC, SRS-2, and CGI-I were compared between the two groups at baseline and at 6 and 12 weeks into treatment. Gut microbiome data were analyzed with the QIIME 2 software package, and functional gene analysis was conducted with PICRUSt-2.Results: We found a significant increase in height (mean difference = 2.68 cm, P < 0.05) and improvement in CGI-I (P < 0.05) in the probiotics group compared to the placebo group. No significant change in weight or psychological measures were observed. Probiotic treatment altered the microbiome composition to favor weight loss and gut health and increased the abundance of antioxidant production-related genes.Conclusions: The findings suggest a novel therapeutic potential for Bifidobacterium animalis subsp. lactis probiotics in Prader-Willi syndrome patients, although further investigation is warranted.

scholarly journals PROVIT: Supplementary Probiotic Treatment and Vitamin B7 in Depression—A Randomized Controlled Trial

Nutrients ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3422
Author(s):  
Eva Z. Reininghaus ◽  
Martina Platzer ◽  
Alexandra Kohlhammer-Dohr ◽  
Carlo Hamm ◽  
Sabrina Mörkl ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Clinical Symptoms ◽  
Psychiatric Symptoms ◽  
Controlled Trial ◽  
Intervention Group ◽  
Double Blind ◽  
16S Rrna Analysis ◽  
Brain Functions ◽  
Β Diversity ◽  
Probiotic Treatment

Gut microbiota are suspected to affect brain functions and behavior as well as lowering inflammation status. Therefore, an effect on depression has already been suggested by recent research. The aim of this randomized double-blind controlled trial was to evaluate the effect of probiotic treatment in depressed individuals. Within inpatient care, 82 currently depressed individuals were randomly assigned to either receive a multistrain probiotic plus biotin treatment or biotin plus placebo for 28 days. Clinical symptoms as well as gut microbiome were analyzed at the begin of the study, after one and after four weeks. After 16S rRNA analysis, microbiome samples were bioinformatically explored using QIIME, SPSS, R and Piphillin. Both groups improved significantly regarding psychiatric symptoms. Ruminococcus gauvreauii and Coprococcus 3 were more abundant and β-diversity was higher in the probiotics group after 28 days. KEGG-analysis showed elevated inflammation-regulatory and metabolic pathways in the intervention group. The elevated abundance of potentially beneficial bacteria after probiotic treatment allows speculations on the functionality of probiotic treatment in depressed individuals. Furthermore, the finding of upregulated vitamin B6 and B7 synthesis underlines the connection between the quality of diet, gut microbiota and mental health through the regulation of metabolic functions, anti-inflammatory and anti-apoptotic properties. Concluding, four-week probiotic plus biotin supplementation, in inpatient individuals with a major depressive disorder diagnosis, showed an overall beneficial effect of clinical treatment. However, probiotic intervention compared to placebo only differed in microbial diversity profile, not in clinical outcome measures.

scholarly journals Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial

2015 ◽  
Vol 114 (10) ◽  
pp. 1638-1646 ◽  
Author(s):  
Dorte Eskesen ◽  
Lillian Jespersen ◽  
Birgit Michelsen ◽  
Peter J. Whorwell ◽  
Stefan Müller-Lissner ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Probiotic Strain ◽  
Well Being ◽  
Abdominal Discomfort ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Bifidobacterium Animalis ◽  
Probiotic Treatment ◽  
Placebo Capsule ◽  
Defecation Frequency

AbstractThe aim of the present study was to investigate the effect of Bifidobacterium animalis subsp. lactis, BB-12®, on two primary end points – defecation frequency and gastrointestinal (GI) well-being – in healthy adults with low defecation frequency and abdominal discomfort. A total of 1248 subjects were included in a randomised, double-blind, placebo-controlled trial. After a 2-week run-in period, subjects were randomised to 1 or 10 billion colony-forming units/d of the probiotic strain BB-12® or a matching placebo capsule once daily for 4 weeks. Subjects completed a diary on bowel habits, relief of abdominal discomfort and symptoms. GI well-being, defined as global relief of abdominal discomfort, did not show significant differences. The OR for having a defecation frequency above baseline for ≥50 % of the time was 1·31 (95 % CI 0·98, 1·75), P=0·071, for probiotic treatment overall. Tightening the criteria for being a responder to an increase of ≥1 d/week for ≥50 % of the time resulted in an OR of 1·55 (95 % CI 1·22, 1·96), P=0·0003, for treatment overall. A treatment effect on average defecation frequency was found (P=0·0065), with the frequency being significantly higher compared with placebo at all weeks for probiotic treatment overall (all P<0·05). Effects on defecation frequency were similar for the two doses tested, suggesting that a ceiling effect was reached with the one billion dose. Overall, 4 weeks’ supplementation with the probiotic strain BB-12® resulted in a clinically relevant benefit on defecation frequency. The results suggest that consumption of BB-12® improves the GI health of individuals whose symptoms are not sufficiently severe to consult a doctor (ISRCTN18128385).

Randomised double blind placebo controlled trial on Lactobacillus reuteri DSM 17938: improvement in symptoms and bowel habit in functional constipation

2018 ◽  
Vol 9 (1) ◽  
pp. 51-60 ◽  
Author(s):  
G. Riezzo ◽  
A. Orlando ◽  
B. D’Attoma ◽  
M. Linsalata ◽  
M. Martulli ◽  
...  
Keyword(s):  
Lactobacillus Reuteri ◽  
Controlled Trial ◽  
Functional Constipation ◽  
Colonic Transit ◽  
Gas Content ◽  
Bowel Habit ◽  
Gut Health ◽  
Double Blind ◽  
Standard Dosage ◽  
Double Blind Clinical Trial

Dysbiosis may contribute to constipation and its symptoms, therefore probiotic administration could improve significantly gut health and functions. The aim of the study was to investigate the effects of a long-lasting administration of Lactobacillus reuteri DSM 17938 (LR DSM 17938) on symptoms and quality of life (QoL) score in patients with functional constipation (FC). 56 FC patients with normal colonic transit time and without anorectal disorders and pelvic floor dysfunctions completed the study. LR DSM 17938 was administered for 105 days in a randomised double-blind clinical trial (28 patients per arm). Individual and cumulative scores including the Constipaq, a modified Constipation Scoring System (CSS) that considers the patient assessment of constipation-QoL (PAC-QoL), were calculated during the preliminary visit (V0), at day 15 (end of the induction period with a LR DSM 17938 double dosage, 4×108 cfu), day 60 (intermediate evaluation) and day 105 (V4) after a standard dosage (2×108 cfu). At the end of treatment, the beneficial effect of LR DSM 17938 compared to placebo was significantly evident for symptoms related to gas content and dysbiosis (abdominal discomfort, pain and bloating), incomplete defecation and helps for defecation (P<0.05). At the end of the whole LR DSM 17938 treatment, a marked and positive effect on both the CSS single and the cumulative items was evident with the exception of unfruitful attempt and Bristol score. Present findings indicate that LR DSM 17938 has an effect on symptoms different from stool consistency, and they suggest that this probiotic can effectively be used in association therapy rather than as single-drug therapy in the management of FC.

scholarly journals The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12® in infant colic: A randomised, double blind, placebo-controlled trial

2019 ◽  
Vol 51 (1) ◽  
pp. 110-120 ◽  
Author(s):  
Rita Nocerino ◽  
Francesca De Filippis ◽  
Gaetano Cecere ◽  
Antonio Marino ◽  
Maria Micillo ◽  
...  
Keyword(s):  
Therapeutic Efficacy ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Bifidobacterium Animalis ◽  
Infant Colic

Probiotic Lactobacillus plantarum IS 10506 supplementation increase SCFA of women with functional constipation

2019 ◽  
Author(s):  
Pratiwi Dyah Kusumo ◽  
Hasan Maulahela ◽  
Amanda Pitarini Utari ◽  
Ingrid S. Surono ◽  
Amin Soebandrio ◽  
...  
Keyword(s):  
Lactobacillus Plantarum ◽  
Short Chain Fatty Acid ◽  
Controlled Trial ◽  
Functional Constipation ◽  
Fermented Milk ◽  
Chain Fatty Acid ◽  
Probiotic Supplementation ◽  
Double Blind ◽  
Probiotic Lactobacillus ◽  
Physiological Abnormalities

Background and Objectives: Gut microbiota influences our health via multiple mechanisms. Microbiota produced Short Chain Fatty Acid (SCFA) as an energy to maintain gut ecosystem and physiology. Dysbiosis is correlated with SCFA imbal- ance which in turn resulted in physiological abnormalities in the intestine, such as functional constipation. Materials and Methods: Randomized Double-Blind Controlled Trial (RCT) was conducted on women with functional constipation (n=37) in the community of Jakarta and profile of SCFA was assessed by using GC-MS from the stool after 21 days supplementation of fermented milk (placebo and probiotic). Results: Probiotic supplementation significantly influenced acetate titer (p=0,032) marginally significant for propionate and butyrate (p=0.063 and p=0.068, respectively) and the respondent with increasing SCFA’s metabolite are higher in probiotic group compared to the respondents in placebo group. Acetate is the highest SCFA titer found in faeces samples of women with functional constipation. Conclusion: Probiotic Lactobacillus plantarum IS 10506 supplementation influenced all the SCFA parameter (acetate, pro- pionate and butyrate).

Sign in / Sign up

Export Citation Format

Share Document